Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPC1 | O15118 | 1/20 | 0.49 |
| ▸ | CA12 | O43570 | 3/20 | 0.49 |
| ▸ | CA1 | P00915 | 3/20 | 0.49 |
| ▸ | CA2 | P00918 | 3/20 | 0.49 |
| ▸ | CA9 | Q16790 | 3/20 | 0.49 |
| ▸ | MEN1 | O00255 | 3/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 3/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.47 |
| ▸ | PKM | P14618 | 1/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.42 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.42 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.42 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.42 |
| ▸ | RAB9A | P51151 | 1/20 | 0.41 |
| ▸ | DRD2 | P14416 | 1/20 | 0.41 |
| ▸ | DRD4 | P21917 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL8135888 | 0.83 | DRD4 (0.55) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL21244056 | 0.81 | CA12 (0.50) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL12156373 | 0.81 | DRD4 (0.56) | NPC1CA12CA1CA2CA9 | |
| Hydrochloric Acid SCHEMBL22729331 | 0.80 | KMT2A (0.49) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL9807625 | 0.79 | NPC1 (0.54) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL21941875 | 0.78 | DRD4 (0.56) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL21017768 | 0.77 | DRD2 (0.59) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL5566464 | 0.76 | CA12 (0.54) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL3594497 | 0.76 | CA12 (0.54) | NPC1CA12CA1CA2CA9 | |
| SCHEMBL485945 | 0.75 | DRD2 (0.55) | NPC1CA12CA1CA2CA9 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | GIVAUDAN SA (CH) | 2012-04-19 | — | — | US | claimed |
| EP-2427170-A2 | ORGANIC COMPOUNDS HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2012-03-14 | — | — | EP | claimed |
| WO-2010128026-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | WO | claimed |
| US-8664261-B2 | Organic compounds having cooling properties | GIVAUDAN S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-8664261-B2 | Organic compounds having cooling properties | GIVAUDAN S.A. (CH) | 2014-03-04 | — | — | US | disclosed |
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | GIVAUDAN SA (CH) | 2012-04-19 | — | — | US | disclosed |
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | GIVAUDAN SA (CH) | 2012-04-19 | — | — | US | disclosed |
| EP-2427170-A2 | ORGANIC COMPOUNDS HAVING COOLING PROPERTIES | Givaudan SA (CH) | 2012-03-14 | — | — | EP | disclosed |
| WO-2010128026-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | WO | disclosed |
| WO-2010128026-A2 | ORGANIC COMPOUNDS | GIVAUDAN SA (CH) | 2010-11-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120095042-A1 | Organic Compounds Having Cooling Properties | ME3, ME2, MSMO1 | NPC1 3345/4885CA12 913/4885CA1 384/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.